{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:44:22Z","timestamp":1792100662691,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.urolonc.2020.04.030","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T07:57:16Z","timestamp":1590393436000},"page":"683.e19-683.e26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells"],"prefix":"10.1016","volume":"38","author":[{"given":"Daniel","family":"Eberli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Kranzb\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Mortezavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Sulser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzan","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2020.04.030_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(05)00034-0","article-title":"Secondary hormonal therapy for advanced prostate cancer","volume":"175","author":"Lam","year":"2006","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.04.030_bib0002","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.030_bib0003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2020.04.030_bib0004","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2020.04.030_bib0005","doi-asserted-by":"crossref","first-page":"728-741","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.030_bib0006","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/pros.23725","article-title":"Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells","volume":"79","author":"Kranzbuhler","year":"2019","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.030_bib0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00345-018-2385-5","article-title":"Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer","volume":"37","author":"Mortezavi","year":"2019","journal-title":"World J Urol"},{"issue":"19","key":"10.1016\/j.urolonc.2020.04.030_bib0008","doi-asserted-by":"crossref","first-page":"31765","DOI":"10.18632\/oncotarget.15986","article-title":"Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death","volume":"8","author":"Mortezavi","year":"2017","journal-title":"Oncotarget"},{"issue":"36","key":"10.1016\/j.urolonc.2020.04.030_bib0009","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1038\/onc.2014.25","article-title":"Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model","volume":"33","author":"Nguyen","year":"2014","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.urolonc.2020.04.030_bib0010","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1074\/jbc.M308576200","article-title":"Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis","volume":"279","author":"Altznauer","year":"2004","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.urolonc.2020.04.030_bib0011","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.04.030_bib0012","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort","volume":"70","author":"Smith","year":"2016","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2020.04.030_bib0013","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.urolonc.2020.04.030_bib0014","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1158\/1078-0432.CCR-16-2509","article-title":"Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone","volume":"23","author":"Rathkopf","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.04.030_bib0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12885-019-5709-y","article-title":"The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels","volume":"19","author":"Werutsky","year":"2019","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2020.04.030_bib0016","first-page":"1","article-title":"Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer","volume":"10","author":"Boudadi","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.urolonc.2020.04.030_bib0017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semcancer.2018.09.003","article-title":"New developments in mechanisms of prostate cancer progression","volume":"57","author":"Howard","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"10.1016\/j.urolonc.2020.04.030_bib0018","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.urolonc.2020.04.030_bib0019","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/annonc\/mdx283","article-title":"Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide","volume":"28","author":"Rathkopf","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2020.04.030_bib0020","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.4161\/auto.22110","article-title":"Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells","volume":"8","author":"Zou","year":"2012","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.urolonc.2020.04.030_bib0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1947601909358324","article-title":"Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors","volume":"1","author":"Wu","year":"2010","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1016\/j.urolonc.2020.04.030_bib0022","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/ncb0910-814","article-title":"Eaten alive: a history of macroautophagy","volume":"12","author":"Yang","year":"2010","journal-title":"Nat Cell Biol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.030_bib0023","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2012.07.054","article-title":"Synergistic killing effect of chloroquine and androgen deprivation in LNCaP cells","volume":"425","author":"Kaini","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.urolonc.2020.04.030_bib0024","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/pros.22658","article-title":"Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis","volume":"73","author":"Boutin","year":"2013","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.030_bib0025","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1074\/jbc.275.2.992","article-title":"Distinct classes of phosphatidylinositol 3\u2032-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells","volume":"275","author":"Petiot","year":"2000","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.urolonc.2020.04.030_bib0026","doi-asserted-by":"crossref","first-page":"10850","DOI":"10.1074\/jbc.M109.080796","article-title":"Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase","volume":"285","author":"Wu","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.urolonc.2020.04.030_bib0027","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrd2272","article-title":"Potential therapeutic applications of autophagy","volume":"6","author":"Rubinsztein","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.urolonc.2020.04.030_bib0028","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1634\/theoncologist.2018-0621","article-title":"Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): phase II trial of high dose pantoprazole (autophagy inhibitor) with docetaxel in metastatic castration-resistant prostate cancer (mCRPC)","volume":"24","author":"Hansen","year":"2019","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.urolonc.2020.04.030_bib0029","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ncb1192","article-title":"Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes","volume":"6","author":"Shimizu","year":"2004","journal-title":"Nat Cell Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.04.030_bib0030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CAD.0000000000000592","article-title":"Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines","volume":"29","author":"Koukourakis","year":"2018","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.urolonc.2020.04.030_bib0031","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort","volume":"70","author":"Smith","year":"2016","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030185X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030185X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:37Z","timestamp":1761041917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392030185X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S107814392030185X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.04.030","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}